# CER-001 Atherosclerosis Regression ACS Trial

Study · id `cardio:ct-nct02484378` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02484378](<https://clinicaltrials.gov/study/NCT02484378>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02484378

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.

## Technical summary

Registry record NCT02484378. Randomized; quadruple masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2016-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 301 participants (enrolled count; ClinicalTrials.gov record NCT02484378, source copy `cardio:ctgov-nct02484378-2019-02-11`, retrieved 2026-10-31)
- Started: 2015-08 (actual) (ClinicalTrials.gov record NCT02484378, source copy `cardio:ctgov-nct02484378-2019-02-11`, retrieved 2026-10-31)
- Primary completion: 2016-11 (actual) (ClinicalTrials.gov record NCT02484378, source copy `cardio:ctgov-nct02484378-2019-02-11`, retrieved 2026-10-31)
- Completion: 2016-12 (actual) (ClinicalTrials.gov record NCT02484378, source copy `cardio:ctgov-nct02484378-2019-02-11`, retrieved 2026-10-31)
- Countries: United States; Australia; Hungary; Netherlands (ClinicalTrials.gov record NCT02484378, source copy `cardio:ctgov-nct02484378-2019-02-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02484378-2019-02-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: CER-001 Atherosclerosis Regression ACS Trial
- Acronym: CARAT
- Condition: Acute Coronary Syndromes
- Intervention (Drug): CER-001
- Intervention (Drug): Placebo
- Lead sponsor: Cerenis Therapeutics, SA
- Lead sponsor class: INDUSTRY
- Collaborator: South Australian Health and Medical Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial (`cardio:pubmed-30046828`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 68da87fbb93e14f10fd06fcea49952a886d0bd935b673bf7b172673a3ad21025
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
